Pharma & Bio
Technology
JWPHARMACEUTICAL Goes Head-to-Head with 6mg ‘Gout Treatment’… Global Competition Also Accelerates
(Graphic: Generative AI)
JWPHARMACEUTICAL(001060)’s new gout drug candidate, “Efamynurad,” has demonstrated its competitiveness at the 6 mg dose—its primary dosage—in a multinational Phase 3 clini…
Technology
BioNexus, a Company in the Government’s Spotlight: CEO Kim Tae-hyung Says, “AI Formulates Hypotheses and Conducts Experiments… It’s Revolutionizing New Drug Development”
Advances in artificial intelligence (AI) are reshaping the process of new drug development. Whereas researchers used to read papers and formulate hypotheses, AI now reads hundreds of thousands of pape…
Technology
BlackRock, Which Suffered Losses with SillaJen and Helixmith: Will Its Latest Bet on K-Bio Pay Off?
BlackRock’s headquarters in New York, U.S. (Photo: Newsis.)
Interest is mounting in the reasons behind BlackRock, the world’s largest asset management firm, expanding its investments in South Kore…
Technology
Why SK BIOPHARMACEUTICALS Is Staking Its Future on Securing IP... The Evergreening Gamble
SK BIOPHARMACEUTICALS’ New Epilepsy Drug Excofry (Photo courtesy of SK BIOPHARMACEUTICALS)
The success or failure of new drug development no longer ends with obtaining approval. “IP management” ha…
Lifestyle
[Exclusive] ECM Skin Booster: Side Effect Reporting Requirements Tightened to “Twice a Year”… Regulatory Framework Outline
As cell-free allogeneic dermal-based extracellular matrix (ECM) skin boosters are reshaping the market, regulatory authorities are taking steps to strengthen safety measures. Rather than creating a ne…
Lifestyle
HK InnoN K-Cap: Three Reasons for Its Competitiveness in China, the Battleground for P-CABs
HK InnoN’s new drug “K-Cap” for gastroesophageal reflux disease (GERD) has begun to gain significant market share in China and has entered a phase of generating royalty revenue. Unlike Takeda Pharmace…
Technology
Kim Hyung-jun, CEO of Able Therapeutics: “Early Detection of Dementia Through Voice… AI Picks It Up”
(Graphic: Generative AI)
“Roses have bloomed in the garden.”Kim Hyung-jun, CEO of Able Therapeutics, recently met with E-Daily’s pharmaceutical and biotech premium content service, Pharm E-Daily, …
Technology
"After Oral Drugs, Next Up Are Indications"... A Look at Novo and Lilly's Next-Generation Pipelines
As the first round of the “weight-loss drug war” between Eli Lilly and Novo Nordisk effectively tilts in Lilly’s favor, the two pharmaceutical giants have entered a high-stakes second round, competing…
Technology
DRTech, TissueGene, and Finemedix All Rally [K-bio Pulse]
On the 13th, three companies in Korea’s pharmaceutical, biotech, and healthcare sectors—#DRTech, #KolonTissueGene, and #FinemediX—all posted gains. DR Tech and FinemediX rose on the back of improved e…
Technology
[Bio Spotlight] DRTECH Corporation Soars to Daily Limit Up… Kolon TissueGene, Inc. Also Rebounds Slightly
On the 13th, in the domestic pharmaceutical, biotech, and healthcare sectors, DRTECH Corporation(214680) Kolon TissueGene, Inc.(950160) #Finemedix Co., Ltd. all posted gains. DRTECH Corporation and Fi…